Search the Newsreel

ARVN Maintains by Evercore ISI Group -- Price Target Lowered to $14.00

Evercore ISI Group has maintained an Outperform rating for Arvinas (ARVN) but lowered its price target from $19.00 to $14.00, reflecting a cautious outlook. Despite being significantly undervalued by GuruFocus's GF Value™ at $31.53 versus a current price of $8.95, the company faces financial …

Arvinas, Inc. Stock 12‑Month Price Target Cut to $13.93, Implies 59% Upside

Arvinas, Inc.'s average 12-month price target has been lowered from $14.23 to $13.93 by 14 analysts, with forecasts ranging from $6 to $21 per share. This new target suggests a potential upside of approximately 59% from the Aug. 7 closing price. The consensus rating …

Precision Trading with Arvinas Inc. (ARVN) Risk Zones

This article provides a detailed AI-driven analysis for Arvinas Inc. (ARVN), highlighting potential trading strategies based on sentiment and risk zones. It outlines long, breakout, and short strategies with specific entry points, targets, and stop losses. The analysis also includes multi-timeframe signal strengths and …

Price to book forward of Arvinas, Inc. – NASDAQ:ARVN

This article provides a financial metric, "Price to book forward," for Arvinas, Inc. (NASDAQ:ARVN). It appears to be a stub or a data point from a financial platform, showing the company's ticker, market, and a period value, but without further elaboration or detailed financial …

Arvinas (NASDAQ:ARVN) Rating Increased to Hold at Wall Street Zen

Wall Street Zen has upgraded Arvinas (NASDAQ:ARVN) from a "Sell" to a "Hold" rating. This upgrade comes despite mixed analyst sentiments and a forecast for a full-year loss, following a significant quarterly earnings beat where Arvinas reported $2.58 EPS against expected a $0.37 loss …

Arvinas Inc (ARVN) Earnings Forecast: Future EPS & Revenue Growth Estimates

This article provides an earnings forecast for Arvinas Inc (ARVN), indicating its current earnings forecast score, average price target, and analyst ratings. Based on 17 analysts, the stock has a "Buy" trend with a target price of $14.00, suggesting a potential upside of 61.90%. …

Arvinas posts corporate presentation highlighting PROTAC degrader pipeline in oncology and neurology

Arvinas recently released a corporate presentation that highlights its PROTAC degrader pipeline, focusing on advancements in oncology and neurology. Key updates include the FDA clearance of VEPPANU for advanced breast cancer and the out-licensing of luxdegalutamide to Novartis, generating over $800 million in non-dilutive …

HC Wainwright Has Pessimistic Outlook of Arvinas Q3 Earnings

Arvinas Inc (ARVN) Stock News Today

This article provides a current snapshot of Arvinas Inc (ARVN) stock information. It includes the latest stock price, market capitalization, and a note indicating that more news, earnings, and analyst ratings are coming soon. The page serves as a placeholder for future updates on …

Enterprise value to revenue forward of Arvinas, Inc. – NASDAQ:ARVN

This article provides a financial snapshot for Arvinas, Inc. (NASDAQ: ARVN), focusing on its enterprise value to revenue forward. It appears to be a financial data point from TradingView, showing the period, value, and change for this specific metric. The content itself is very …

Arvinas (NASDAQ:ARVN) Trading Down 7.8% on Analyst Downgrade

Arvinas (NASDAQ:ARVN) shares dropped 7.8% after Wells Fargo downgraded the stock from "overweight" to "equal weight." Despite this, the company reported a significant second-quarter beat with EPS of $2.58 and revenue of $249.7 million, largely due to licensing and milestone activities. Arvinas also received …

Arvinas Q2 2026 earnings: Licensing revenue drives a return to profit

Arvinas (ARVN) reported a significant turnaround in Q2 2026, driven by a surge in licensing revenue from its collaboration with Pfizer and the Rigel license agreement, leading to a profit of $2.58 diluted EPS. The company's revenue reached $249.7 million, up from $22.4 million …

Arvinas (ARVN) Stock Jumps As Profit Windfall Sparks Durability Debate

Arvinas (ARVN) stock surged 11.7% after reporting Q2 earnings, driven by a significant profit from licensing and collaboration revenue. Despite this windfall, concerns remain about the durability of its profit, as much of it was from one-off payments rather than recurring income, leading to …

Arvinas (ARVN) holder Noah C. Berkowitz plans sale of 30,000 shares

Noah C. Berkowitz, a shareholder of Arvinas (ARVN), has filed notice to sell 30,000 shares of common stock for an approximate aggregate price of $264,000 through Morgan Stanley. The filing also disclosed a previous sale of 24,000 shares on July 9, 2026, for $201,528. …

Arvinas (NASDAQ: ARVN) posts $169.4M profit on VEPPANU and Rigel deals

Arvinas (NASDAQ: ARVN) reported a significant financial turnaround in Q2 2026, posting a net income of $169.4 million and revenue of $249.7 million, compared to a net loss of $61.2 million and $22.4 million revenue in Q2 2025. This profitability was largely driven by …

Arvinas, Inc. Stock 12‑Month Price Target Cut to $14.85, Implies 84% Upside

Arvinas, Inc.'s average 12-month price target has been lowered from $15.08 to $14.85 by 13 analysts, with individual forecasts ranging from $6 to $24. This updated target suggests an 84% potential upside based on the Aug. 3 closing price. Despite the price target cut, …

ARVINAS, INC. 2026: Revenue $249.7M, EPS $2.58— 10-Q Summary

ARVINAS, INC. reported significant financial growth in 2026, with revenue reaching $249.7M and diluted EPS at $2.58, largely driven by licensing and milestone recognition. Key business highlights include FDA approval for VEPPANU and its out-license to Rigel, leading to substantial upfront and milestone payments. …

BTIG reiterates Arvinas stock Buy rating on pipeline execution

BTIG reiterated a Buy rating and an $18.00 price target on Arvinas Inc. (NASDAQ:ARVN) following the company's strong second-quarter earnings report. Arvinas reported significant GAAP revenue of $249.7 million and a cash position of $567.9 million, providing runway into the second half of 2028. …

Wedbush Adjusts Price Target on Arvinas to $12 From $11, Maintains Neutral Rating

Wedbush has increased its price target for Arvinas (ARVN) to $12 from $11, while maintaining a Neutral rating on the stock. This adjustment comes as Arvinas continues to advance its PROTAC protein degrader platform and multiple investigational drugs through clinical development.

Arvinas (NASDAQ:ARVN) Trading 14.8% Higher Following Better-Than-Expected Earnings

Arvinas (NASDAQ:ARVN) saw its shares surge 14.8% after reporting better-than-expected quarterly earnings and revenue. The company beat consensus EPS estimates by $2.95 and reported a 1,014.7% year-over-year revenue increase. Despite mixed analyst ratings, the stock holds a consensus Hold rating with a target price …

Arvinas (NASDAQ:ARVN) Releases Earnings Results, Beats Expectations By $2.95 EPS

Arvinas Inc (ARVN) is preparing to release its Q2 2026 earnings on August 4, 2026, with analysts forecasting $32.54 million in revenue and an EPS of -$0.44. Despite missing previous quarter's estimates, the GF Value suggests a 34.37% upside from its current price, and …

Transcript: Arvinas Q2 2026 Earnings Conference Call

Arvinas (NASDAQ: ARVN) reported its Q2 2026 earnings, highlighting significant strategic milestones including FDA approval of their first PROTAC degrader, Vepanu, and an out-licensing deal with Rigel Pharmaceuticals. The company announced $249.7 million in revenue for the quarter and a strong cash position of …

Arvinas reports $249.7M Q2 revenue, $169.4M net income and guidance into H2 2028

Arvinas reported strong financial results for Q2 2026, with revenue of $249.7 million and net income of $169.4 million, largely due to collaboration and licensing agreements. The company announced that its cash reserves of $567.9 million are sufficient to fund operations into the second …

Arvinas Q2 Earnings Call Highlights

ARVINAS ($ARVN) Releases Q2 2026 Earnings

Arvinas Inc (ARVN) is preparing to release its Q2 2026 earnings on August 4, 2026, with analysts forecasting $32.54 million in revenue and an EPS of -$0.44. Despite missing previous quarter's estimates, the GF Value suggests a 34.37% upside from its current price, and …

Arvinas earnings beat by $2.96, revenue topped estimates

Earnings To Watch: Arvinas Inc (ARVN) Q2 2026 -- GF Value Sees 34% Upside

Arvinas Inc (ARVN) is preparing to release its Q2 2026 earnings on August 4, 2026, with analysts forecasting $32.54 million in revenue and an EPS of -$0.44. Despite missing previous quarter's estimates, the GF Value suggests a 34.37% upside from its current price, and …

Price to sales forward of Arvinas, Inc. – NASDAQ:ARVN

This article provides financial information for Arvinas, Inc. (NASDAQ: ARVN), specifically focusing on its forward price-to-sales ratio. It indicates that the market was closed at the time of publication and no trades were made. The content is part of a larger financial data platform.

Arvinas Inc (ARVN) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis of Arvinas Inc (ARVN), noting its current valuation score of 6.66 within the Biotechnology & Medical Research industry. It details the company's current P/E ratio, contrasting it with recent highs and lows. The report also indicates that relevant …

Arvinas (ARVN) Projected to Announce Quarterly Earnings on Wednesday

Arvinas (ARVN) is expected to report its Q2 2026 earnings before market open on Wednesday, August 5th, with analysts projecting a loss of $0.24 per share and revenue of $60.7 million. The company's previous quarter showed a narrower-than-expected loss of $0.90 per share despite …

ARVN|Arvinas Inc|Price:8.230|Chg%:+0.030

This article provides a comprehensive stock analysis of Arvinas Inc (ARVN), highlighting its healthy fundamentals, significant growth potential, and "fairly valued" status. It notes high institutional ownership and multiple "Buy" ratings from analysts, despite a medium-term expectation for the stock price to trend down …

Arvinas Inc (ARVN) Institutional Confidence

Arvinas Inc (ARVN) has an institutional shareholding score of 7.00, placing it 80th out of 384 in the Biotechnology & Medical Research industry. The institutional shareholding proportion is 83.59%, which is a 50.35% decrease quarter-over-quarter. Bill Nygren | OAKMX is the largest institutional shareholder, …

Technical Reactions to ARVN Trends in Macro Strategies

This article provides a technical analysis of Arvinas Inc. (NASDAQ: ARVN), highlighting a neutral near-term sentiment with potential for moderate mid-term weakness. It identifies a significant risk-reward setup targeting a 30.2% gain versus a 0.3% risk. The analysis also details institutional trading strategies, including …